What does an elevated hs CRP (high-sensitivity C-reactive protein) level indicate?

Elevated hs-CRP: Meaning and Clinical Significance

An elevated high-sensitivity C-reactive protein (hs-CRP) level primarily indicates the presence of systemic inflammation and serves as an important cardiovascular risk marker, with levels above 3.0 mg/L associated with high cardiovascular risk that may warrant more aggressive preventive therapies. 1

Understanding hs-CRP Values

hs-CRP levels can be categorized into risk categories:

• Low risk: <1.0 mg/L
• Average risk: 1.0-3.0 mg/L
• High risk: >3.0 mg/L
• Mild inflammation: 10-40 mg/L
• Acute inflammation/bacterial infection: 40-200 mg/L
• Severe acute illness: >500 mg/L

1, 2

Clinical Significance of Elevated hs-CRP

Cardiovascular Risk Assessment

• Elevated hs-CRP consistently predicts new coronary events in patients with unstable angina and acute myocardial infarction 1
• hs-CRP is a stronger predictor of cardiovascular risk than LDL cholesterol in some studies 3
• For patients with acute coronary syndromes, a cutpoint of 10 mg/L may have better predictive qualities, whereas 3 mg/L is more useful in stable coronary disease 1
• Elevated hs-CRP predicts recurrent myocardial infarction independent of troponins 1

Conditions Associated with Increased hs-CRP Levels

• Cardiovascular factors: Elevated blood pressure, low HDL/high triglycerides 1
• Metabolic factors: Elevated body mass index, metabolic syndrome/diabetes mellitus 1
• Lifestyle factors: Cigarette smoking, estrogen/progestogen hormone use 1
• Inflammatory conditions: Chronic infections (gingivitis, bronchitis), chronic inflammation (rheumatoid arthritis) 1
• Other conditions: Autoimmune diseases, neurodegenerative disorders, and malignancies 2

Clinical Application of hs-CRP Testing

When to Measure hs-CRP

• Primary prevention: Recommended (Class IIa) in intermediate-risk patients (10-20% 10-year CHD risk) to direct further evaluation and therapy 1
• Secondary prevention: May be measured (Class IIa) among patients with known CHD to identify those who might benefit from more aggressive risk-reduction strategies 1
• Discretionary use: Can be used (Class IIb) as part of global risk assessment for patients without known CVD at the physician's discretion 1

Proper Testing Protocol

• For accurate cardiovascular risk assessment, obtain two measurements (optimally 2 weeks apart) to determine baseline hs-CRP levels 1
• Express hs-CRP levels in mg/L to one decimal point 1
• Wait until resolution of any acute inflammatory stimulus before testing for cardiovascular risk assessment 1

Important Caveats and Pitfalls

• hs-CRP is not specific to any single disease state and should be interpreted in clinical context 4
• Persistently unexplained marked elevation of hs-CRP (>10 mg/L) after repeated testing warrants evaluation for non-cardiovascular causes such as infection or inflammation 1
• The direction of change in hs-CRP levels over time is often more informative than a single value 1
• hs-CRP has not been a good predictor of the extent of atherosclerotic disease, showing poor correlations with tests that quantify atherosclerosis extent 1
• Factors that can decrease hs-CRP levels include moderate alcohol consumption, increased activity/endurance exercise, weight loss, and medications (statins, fibrates, niacin) 1

Clinical Decision Making

• For patients with intermediate cardiovascular risk (10-20% 10-year risk), an elevated hs-CRP (>3 mg/L) may reclassify them to high risk, potentially warranting more aggressive preventive therapies 1
• Application of secondary prevention measures should not depend solely on hs-CRP determination (Class III, Level of Evidence A) 1
• Prospective randomized clinical studies are needed to establish the benefits of hs-CRP measurement on clinical outcomes 1

Remember that while hs-CRP provides valuable information about inflammation and cardiovascular risk, it should be interpreted as part of a comprehensive risk assessment rather than in isolation.